Psychosocial and behavioral support for stem cell transplant patients and their family caregivers
Official title: Adapting After Discharge From Allogeneic SCT: Partnering Together; Dyadic Intervention to Improve Patient-Family Caregiver Team-Based Management of the Medical Regimen After Allogeneic Hematopoietic Cell Transplantation
Run by University of Pittsburgh · NCT07107165 · Data updated 2026-11-12
This project tests two brief four-session video counseling programs to help stem cell transplant patients and their family caregivers manage care and stick to medical instructions after hospital discharge.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 208 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | June 2027 |
| Study ends | July 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT07107165 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults receiving a stem cell transplant at the University of Pittsburgh Hillman Cancer Center who have an adult family caregiver willing to participate, are English-speaking, have not had a prior transplant, and accept randomization.
✕Probably not a fit
Patients without an available family caregiver, non-English speakers, those with a prior stem cell transplant, those unwilling to be randomized, or those lacking access to videoconferencing are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized controlled trial enrolling patient–caregiver dyads after hematopoietic stem cell transplant to compare a skills-learning intervention versus a supportive-care intervention. Each intervention includes four live videoconference sessions delivered to the dyad, with 52 dyads randomized to each arm. Patients and caregivers complete questionnaires at baseline and at 1, 5, 12, and 24 weeks to track adherence, perceived task efficacy, and psychosocial outcomes. The trial focuses on short, scalable psychosocial support to improve post-discharge self-management.
Why it matters
Potential benefit: If successful, the interventions could improve patient adherence to the transplant care regimen, reduce caregiver strain, and improve short-term psychosocial and health-related outcomes.
How similar studies have gone: Related psychosocial and problem-solving interventions in oncology and transplant settings have shown promising effects on adherence and caregiver outcomes, but brief four-session dyadic programs delivered by videoconference are less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient undergoing a stem cell transplant at the University of Pittsburgh Hillman Cancer Center * 18 years or older * having a family caregiver age 18 years or older also willing to participate in the study * willing to accept randomization Exclusion Criteria: * Prior history of stem cell transplant * Non-English speaking
Where it's running
-
University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Donna Posluszny, PhD
- Email: poslusznydm@upmc.edu
- Phone: 412-623-5966
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Middle East study of bloodstream infections in blood cancer patients and HSCT recipients
This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.
-
G‑CSF plus IL‑11 for faster blood recovery after autologous stem cell transplant
This phase 2 trial will test whether adding IL‑11 to G‑CSF improves mobilization and speeds platelet and red blood cell recovery in adults having autologous stem cell transplant for multiple myeloma or lymphoma.
-
Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant
This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.
-
Optimizing and Unifying Management of HSCT in Pediatric ALL
This trial tests a harmonized HSCT approach for children and young people with ALL, aiming to reduce transplant-related risks and improve long-term outcomes.
-
Ruxolitinib-enhanced haploidentical transplant for children and young adults with sickle cell disease
This trial will test whether adding ruxolitinib to a reduced-intensity haploidentical transplant lowers the risk of graft failure in children and young adults with sickle cell disease.
-
Improving outcomes for stem cell transplant patients using an intervention website
This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.